Вирусологическая и иммунологическая эффективность метаболически благоприятных схем антиретровирусной терапии у больных ВИЧ-инфекцией, ранее не получавших лечения

The objective :  to study efficacy and safety of metabolically favorable antiretroviral therapy regimens ( ART ), their effect on  HIV RNA  levels, levels of  CD 4,  CD 8 T lymphocytes, and the ratio of  CD 4/ C D 8 in  HIV  patients who had no previous treatment. Subjects and methods .  The study included 80 patients with  HIV  infection who no received  ART  previously, 67 of them – without clinical manifestations of  HIV  infection, 13 – with  HIV  associated diseases. The virological and immunological efficacy of three  ART  regimens was evaluated: rilpivirine + emtricitabine + tenofovir ( RPV  +  FTC  +  TDF ); dolutegravir, emtricitabine, tenofovir ( DTG ,  FTC ,  TDF ); raltegravir, etravirine, lamivudine ( RAL ,  ETR , 3 TC ) during the first 6 months of treatment. Results .  By the end of the 6th month of  ART , the rate of decrease of viral load compared to the initial level increased in the series  RPV  +  FTS  +  TDF < RAL ,  ETR , 3 TC < DTG ,  FTC ,  TDF . The number of  CD 4  T-l ymphocytes and the ratio of  CD 4/ C D 8 increased in all three  ART  regimens; the number of  CD 8  T-l ymphocytes varied depending on the treatment regimen, the presence or absence of clinical manifestations. The assessment of  ART  efficacy should be based on the clinical signs of  HIV  infection. To assess treatment efficacy, it is necessary to control the viral load and three immunological parameters: the number of  CD 4,  CD 8  T-l ymphocytes, and the ratio of  CD 4/ C D 8.